Vats Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 30-07-2024
- Paid Up Capital ₹ 0.50 M
as on 30-07-2024
- Company Age 47 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 83.17 Cr
as on 30-07-2024
- Satisfied Charges ₹ 2.63 M
as on 30-07-2024
- Revenue %
(FY 2023)
- Profit 60.03%
(FY 2023)
- Ebitda 60.03%
(FY 2023)
- Net Worth -0.12%
(FY 2023)
- Total Assets 0.54%
(FY 2023)
About Vats Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹83.17 Cr. The company has closed loans amounting to ₹2.63 M, as per Ministry of Corporate Affairs (MCA) records.
Umesh Maheshwari and Rajesh Maheshwari serve as directors at the Company.
- CIN/LLPIN
U24231UP1977PTC004468
- Company No.
004468
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 1977
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Uttar Pradesh, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vats Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Maheshwari  | Director | 10-Apr-2013 | Current |
| Rajesh Maheshwari | Director | 22-Mar-2013 | Current |
Financial Performance and Corporate Structure Insights of Vats Pharma.
Vats Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 60.03% increase in profit. The company's net worth dipped by a decrease of 0.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vats Pharma?
In 2023, Vats Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhatter Metals Private LimitedActive 28 years 11 monthsUmesh Maheshwari and Rajesh Maheshwari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Jul 2023 | ₹19.23 Cr | Open |
Others Creation Date: 20 May 2020 | ₹4.95 Cr | Open |
Others Creation Date: 28 Mar 2018 | ₹57.84 Cr | Open |
How Many Employees Work at Vats Pharma?
Unlock and access historical data on people associated with Vats Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vats Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vats Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
